Retatrutide API Manufacturers and Suppliers

Retatrutide (also known as LY3437943) is an investigational triple receptor agonist targeting GIP, GLP-1, and glucagon receptors, currently under development by Eli Lilly. A Phase 2 trial published in the New England Journal of Medicine (June 2023) reported up to 24.2% mean weight reduction at 48 weeks in participants with obesity, with ongoing Phase 3 trials for obesity and type 2 diabetes. Retatrutide was specifically cited in FDA warning letters to Prime Vitality (December 2024) and Xcel Research (December 2024) for unauthorized sales with therapeutic claims including weight loss, glycemic control improvement, and liver fat reduction. As an investigational drug without FDA approval, retatrutide is legally available only through authorized clinical trials. Buyer verification should confirm that any supplier offering retatrutide can document a valid regulatory basis for distribution.

Directory listing last reviewed October 2026.